Diazoxide micellar composition for preventing or treating l-dopa-induced dyskinesia

TWI944943BActive Publication Date: 2026-11-01NAT CHENG KUNG UNIV +1
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
TW114144400
Authority / Receiving Office
TW · TW
Patent Type
Patents
Current Assignee / Owner
Priority Date
2024-12-06
Filing Date
2025-11-14
Publication Date
2026-11-01
Estimated Expiration
2045-11-13

AI Technical Summary

Technical Problem

Long-term use of levodopa for Parkinson's disease treatment leads to levodopa-induced dyskinesia, characterized by involuntary movements such as dystonia and choreiform movements, which current treatments fail to adequately address.

Method used

A pharmaceutical composition comprising a potassium channel opener, such as diazoxide, embedded in microcells with a size of 35-70 nanometers, administered nasally to modulate dopamine levels and reduce involuntary movements.

Benefits of technology

The composition effectively reduces levodopa-induced dyskinesia by improving dopamine secretion and neuronal function, as demonstrated by reduced abnormal involuntary movement scores and increased tyrosine hydroxylase neuron counts in animal models.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure TWG2TB001919198_001
    Figure TWG2TB001919198_001
  • Figure TWG2TB001919198_002
    Figure TWG2TB001919198_002
  • Figure TWG2TB001919198_003
    Figure TWG2TB001919198_003
Patent Text Reader

Abstract

This invention provides a diazoxide microcell composition for the prevention or treatment of levodopa-induced involuntary movements. The diazoxide is embedded or coated within microcells formed of a block copolymer, wherein the block copolymer is mPEG-b-PCL or mPEG-b-PCL-PNA. This diazoxide microcell composition can be administered intranasally for the prevention or treatment of levodopa-induced involuntary movements in individuals with Parkinson's disease after levodopa treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This field relates to the medical field, specifically to the prevention or treatment of neurodegenerative diseases. Prior Technology

[0002] The main pathological feature of Parkinson's disease is the neurodegeneration of the nigrostriatal pathway, which is formed by dopamine neurons projecting from the substantia nigra pars compacta (SNpc) to the striatum (STR). When the dopamine neurons in the nigrostriatal pathway degenerate, insufficient dopamine secretion leads to problems in the neural circuit's control of movement, resulting in typical Parkinson's symptoms such as bradykinesia, tremors, and balance disorders.

[0003] Levodopa (L-DOPA) is a first-line treatment for Parkinson's disease. It is converted to dopamine by dopamine decarboxylase and stimulates the neurons involved. Clinically, it is often used in combination with decarboxylase inhibitors to ensure more levodopa crosses the blood-brain barrier and is converted to dopamine in the brain. While this treatment can maintain good efficacy for about 2 to 5 years, long-term (about 6 to 10 years) use of levodopa may lead to decreased efficacy and side effects, including a narrower range of responses, the need for higher doses, and the potential for L-DOPA-induced dyskinesia. These involuntary movements include dystonia, choreiform movements, and athetoid movements, which can significantly impact a patient's quality of life.

[0004] Therefore, how to prevent or treat levodopa-induced involuntary movements is an urgent problem that needs to be solved. Summary of the Invention

[0005] To address the aforementioned problems, the present invention provides a pharmaceutical composition for the prevention or treatment of involuntary movements associated with dopamine dysfunction, comprising: a potassium channel opener and a pharmaceutically acceptable carrier. In some embodiments, the involuntary movements associated with dopamine dysfunction include L-DOPA-induced dyskinesia. In some embodiments, the composition is administered nasally. In some embodiments, the composition is in the form of a liquid, a dry powder, a suspension, or any combination thereof.

[0006] In some embodiments, the potassium channel opener includes an ATP-sensitive potassium channel opener. In some embodiments, the ATP-sensitive potassium channel opener includes diazoxide. In some embodiments, the potassium channel opener is embedded in or coated within the microcell.

[0007] In some embodiments, the pharmaceutically acceptable carrier is a microcell. In some embodiments, the particle size of the microcell is between 35 nanometers and 70 nanometers (nm). In some embodiments, the threshold voltage of the microcell is between -15 millivolts and -2 millivolts (mV). In some embodiments, the composition of the microcell includes a block copolymer. In some embodiments, the weight ratio of the potassium ion channel opener to the microcell is 1:(100 to 1500).

[0008] In another aspect, the present invention provides the use of the composition as described above in the preparation of a medicament for the prevention or treatment of involuntary movements associated with dopamine dysfunction, wherein the route of administration of the medicament includes the nasal cavity. Simple Explanation of the Diagram

[0009] Figure 1 illustrates the process of establishing a mouse model of involuntary movement induced by levodopamine.

[0010] Figure 2 illustrates the results of establishing a mouse model of involuntary movement induced by levodopamine.

[0011] Figures 3A and 3B illustrate the changes in involuntary movement scores (AIM scores) over time with levodopamine treatment. Figure 3A measures the AIM score of the forelimb, while Figure 3B measures the AIM score of the axial region. # represents p < 0.05, and ## represents p < 0.01. Differences were assessed using Student's t-test or two-way ANOVA, combined with Tukey's post-hoc test.

[0012] Figure 4 is a flowchart of the first experiment.

[0013] Figure 5A shows immunohistochemical staining of tyrosine hydroxylase (TH) in the striatum (left half) and substantia nigra (right half), used to observe the differences produced by treatment with different drugs.

[0014] Figure 5B shows a quantitative map of the effect of different drug treatments on the staining intensity of tyrosine hydroxylase (TH) in the striatum.

[0015] Figure 5C shows a quantitative map of the effect of different drug treatments on the number of tyrosine hydroxylase (TH) cells in the substantia nigra.

[0016] Figure 6A shows the effect of different drug treatments on the AIM score of the forelimb.

[0017] Figure 6B shows the effect of different drug treatments on the axial AIM score.

[0018] Figure 7A is a flowchart of the steps for the synthesis and detection of microcells.

[0019] Figure 7B shows a more detailed microcell detection procedure.

[0020] Figure 8A shows the reaction process for synthesizing the fluorescent molecule PNA.

[0021] Figure 8B shows the reaction process for synthesizing the polymer mPEG-b-PCL.

[0022] Figure 8C shows the reaction process of combining the fluorescent molecule PNA and the polymer mPEG-b-PCL.

[0023] Figure 9A shows the proton NMR spectrum of the polymer mPEG-b-PCL.

[0024] Figure 9B shows the proton NMR spectrum of the microcellular molecule, namely PPP or mPEG-b-PCL-PNA.

[0025] Figures 10A to 10C are calibration curves.

[0026] Figure 11A shows the image results of the microcell stability test.

[0027] Figures 11B and 11C show the quantitative results of the stability test of microcells.

[0028] Figure 12A shows the calibration curve of diazoxide.

[0029] Figure 12B is a comparison chart of permeability coefficients.

[0030] Figure 13 is a photographic image of the olfactory tubercle region, illustrating that diazoxide-containing microcells delivered via nasal delivery can enter the olfactory tubercle region.

[0031] Figure 14 shows the flowchart of the second experiment. The number of mice in the control group (CTR) was 5 (N=5), the number of mice in the lesion group (6OHDA-saline) was 5 (N=5), the number of mice in the FAUC-365 treatment group was 10 (N=10), and the number of mice in the treatment group (6OHDA-Diz) coated with diazoxide microcells (shown as diazoxide) was 10 (N=10).

[0032] Figures 15A and 15B compare the scores of axial involuntary movements and forelimb involuntary movements, respectively, illustrating the therapeutic effect of diazoxide-coated microcells. The CTR shown on the X-axis represents the control group, 6OHDA represents the lesioning group, 6OHDA / Dia+ represents the treatment group with diazoxide-coated microcells, and 6OHDA / FAUC represents the FAUC-365 treatment group. * represents p < 0.05, ** represents p < 0.01, and *** represents p < 0.001. Differences were assessed using one-way ANOVA and Tukey's post-hoc test.

[0033] Figure 16A shows the immunohistochemical staining of the striatum and substantia nigra of a mouse.

[0034] Figure 16B shows the immunohistochemical staining of the striatum and substantia nigra of a mouse, with TH fluorescence intensity quantification; where L corresponds to the lesion side as shown in Figure 16A, and NL corresponds to the non-lesion side as shown in Figure 16A.

[0035] Figure 16C shows the number of neurons in the substantia nigra of the mouse striatum and substantia nigra through immunohistochemical staining. In this figure, L corresponds to the lesion side as shown in Figure 16A, and NL corresponds to the non-lesion side as shown in Figure 16A.

[0036] Figure 17 shows a fluorescence image and a brain anatomy reference diagram to illustrate the specific location of diazoxide-containing microcells in the mouse brain after intranasal administration.

[0037] Figures 18A and 18B show the results of the insulin tolerance test and the glucose tolerance test, respectively. Implementation

[0038] The present invention provides a pharmaceutical composition for the prevention or treatment of involuntary movements associated with dopamine dysfunction, comprising: a potassium channel opener (K+ channel opener) and a pharmaceutically acceptable carrier, wherein the treatment includes relief, prevention of deterioration, delay of progression or cure.

[0039] In some embodiments, the potassium ion channel opener is a compound that, upon contact with an ion channel protein, can directly or indirectly cause a conformational change, enabling potassium ions to penetrate the cell membrane through the ion channel. This ion channel can be present in mammalian cells, including nerve cells, cardiomyocytes, skeletal muscle cells, renal epithelial cells, pancreatic β cells, or vascular endothelial cells, and is not limited thereto. Specifically, the nerve cells can refer to neurons. In some embodiments, the ion channel includes a cation channel protein, which includes a potassium channel, specifically an ATP-sensitive potassium channel (KATP).

[0040] Therefore, in some embodiments, the potassium channel opener may be an ATP-sensitive potassium channel opener. In some embodiments, the ATP-sensitive potassium channel opener includes: diazoxide, pinadil, nicorandil, minoxidil, retigabine, or any combination thereof.

[0041] In some embodiments, the pharmaceutically acceptable carrier is a particulate carrier, the surface of which may be charged or neutral.

[0042] In some embodiments, the particulate carrier comprises a polymer chain, which may be a block copolymer having a hydrophilic block and / or a hydrophobic block; thus, it can also be understood that in some embodiments, the polymer chain has both a hydrophilic tail and a hydrophobic tail. In some embodiments, the particulate carrier has a core-shell structure, wherein the core-shell structure includes a core portion and an outer shell portion, the core portion being formed by the hydrophobic tail portion and the outer shell portion being formed by the hydrophilic tail portion.

[0043] In some embodiments, the hydrophilic segment includes polyethylene glycol (PEG), polyvinylpyrrolidone (PVP), or any combination thereof, but is not limited thereto.

[0044] In some embodiments, the lipophilic segment includes polylactic acid (PLA), poly-ε-caprolactone (PCL), polyphenylene oxide (PPO), or any combination thereof, but is not limited thereto.

[0045] In some embodiments, the particulate carrier comprises an environmentally responsive polymer, which includes a temperature-responsive polymer, a pH-responsive polymer, a light-responsive polymer, an ion-responsive polymer, or any combination thereof, but is not limited thereto; wherein the temperature-responsive polymer may be poly(N-isopropylacrylamide), and the pH-responsive polymer may be poly(2-(diisopropylamino)methyl methacrylate), PDPA. It is understood that the environmentally responsive polymer may serve as a segment of the block copolymer.

[0046] In some embodiments, the particulate carrier comprises a fluorescent compound having a nitroimide structure, such as 1,8-naphthalimide or a derivative thereof. It is understood that the fluorescent compound may be attached to the end of a polymer chain or as a segment of a block copolymer, and is not limited thereto.

[0047] In some embodiments, the block copolymer is mPEG-b-PCL or mPEG-b-PCL-PNA.

[0048] In some embodiments, the potassium ion channel opener is distributed within or on the surface of the particulate carrier. In some embodiments, the particle size of the particulate carrier is between 5 and 500 nanometers (nm).

[0049] In some embodiments, the particulate carrier includes: microcells, liposomes, polymeric nanoparticles, nanogels, microgels, polymer vesicles, or any combination thereof.

[0050] In some embodiments, the potassium ion channel opener is embedded or encapsulated within the microcell. In some embodiments, the particle size of the microcell is between 35 nanometers and 70 nanometers (nm), for example: 35, 40, 45, 50, 55, 60, 65, or 70 nanometers. In some embodiments, the zeta potential of the microcell is between -50 millivolts and -1 millivolt (mV), preferably between -15 millivolts and -2 millivolts (mV), for example: -15, -14, -13, -12, -11, -10, -9, -8, -7, -6, -5, -4, -3, or -2 millivolts.

[0051] In some embodiments, the weight ratio of the potassium ion channel opener to the microcell is 1:(100 to 1500) or 1:(200 to 1000). For example, the weight ratio of the potassium ion channel opener to the microcell can be 1:100, 1:150, 1:200, 1:250, 1:300, 1:350, 1:400, 1:450, 1:500, 1:550, 1:600, 1:650, 1:700, 1:750, 1:800, 1:850, 1:900, 1:950, 1:1000, 1:1050, 1:1100, 1:1150, 1:1200, 1:1250, 1:1300, 1:1350, 1:1400, 1:1450, or 1:1500.

[0052] In some embodiments, the pharmaceutical composition is administered in an effective dose to an individual, which includes, but is not limited to, mammals such as humans, dogs, cats, cattle, pigs, horses, mice, rats, rabbits, or monkeys.

[0053] In some embodiments, the individual is a mouse, and the effective dose is selected from any value between 0.001 mg / kg and 1 mg / kg. In some preferred embodiments, the individual is a mouse, and the effective dose is selected from any value between 0.01 mg / kg and 0.1 mg / kg, for example, the effective dose is 0.01 mg / kg, 0.02 mg / kg, 0.03 mg / kg, 0.04 mg / kg, 0.05 mg / kg, 0.06 mg / kg, 0.07 mg / kg, 0.08 mg / kg, 0.09 mg / kg, or 0.1 mg / kg.

[0054] Based on the human equivalent dose (HED), in some embodiments, the individual is a human, and the effective dose is selected from any value between 0.08 µg / kg and 120 µg / kg. In some preferred embodiments, the individual is a human, and the effective dose is selected from any value between 0.8 µg / kg and 12 µg / kg, for example, the effective dose is 0.81 µg / kg, 1.62 µg / kg, 2.43 µg / kg, 3.24 µg / kg, 4.06 µg / kg, 4.87 µg / kg, 5.68 µg / kg, 6.49 µg / kg, 7.30 µg / kg, 8.11 µg / kg, or 10.00 µg / kg.

[0055] As mentioned above, dopamine is a neurotransmitter that can exert multiple effects on the nervous system of humans or animals, including stimulation, inhibition, and feedback, leading to physiological or psychological changes. In specific physiological environments, for example, the synapse of a first neuron can secrete dopamine, which travels through the synaptic cleft and is received by the synapse of a second neuron. In some embodiments, the dopamine includes levodopa (L-DOPA) or dextrodopa (D-DOPA); in some preferred embodiments, the dopamine is levodopa.

[0056] As mentioned above, "dopaminergic dysfunction" can refer to impaired dopamine secretion and / or reception between neurons, or it can refer to changes in dopamine concentration in the synaptic cleft, leading to physiological or psychological alterations or abnormalities in an individual. These physiological or psychological abnormalities include motor abnormalities, cognitive abnormalities, and emotional abnormalities. It can also be understood that dopaminergic dysfunction can be primary or secondary.

[0057] The aforementioned motor abnormalities include "involuntary movements" (or abnormal involuntary movements, AIM) as described above. These involuntary movements include dyskinesia, which may be selected from one or more of the following: tremor, chorea, akathisia, tics, myoclonus, and dystonia.

[0058] It should be further understood that the reception of dopamine by this neuron is mediated by a dopamine receptor, which includes D1-like family receptors, including D1 and D5 receptors; and D2-like family receptors, including D2, D3 and D4 receptors.

[0059] In some embodiments, the dopamine dysfunction may be caused by drug treatment; for example, the involuntary movements associated with the dopamine dysfunction may be related to the treatment of Parkinson's disease. More specifically, the involuntary movements associated with the dopamine dysfunction include L-DOPA-induced dyskinesia (LID), which is caused by long-term use of levodapamine to treat Parkinson's disease.

[0060] Furthermore, this levodopa-induced involuntary movement was caused by abnormal activation of medium spiny neurons (MSNs) in the striatum (STR). In particular, the expression of D1 and D2 family dopamine receptors in the striatum of individuals with Parkinson's disease was higher than that of normal individuals.

[0061] In some embodiments, the pharmaceutical composition prevents or treats L-DOPA-induced dyskinesia by reducing the expression of the dopamine receptor in neurons. Because dopamine D3 receptors belong to the D2 family and exhibit high structural similarity, but D3 receptors are primarily distributed in the limbic emotional system, in some preferred embodiments, dopamine D3 receptor antagonists are used to treat L-DOPA-induced dyskinesia (LID).

[0062] In some embodiments, the pharmaceutical composition is administered via the nasal cavity.

[0063] In some embodiments, the dosage form of the composition includes liquid, dry powder, suspension, or any combination thereof, but it is not excluded that it may be in the form of ointment, which is beneficial for nasal administration. In some embodiments, the composition may be a nasal inhaler or a nasal spray.

[0064] In some embodiments, the composition is used to prepare a medicament for the prevention or treatment of involuntary movements associated with dopamine dysfunction, wherein the route of administration of the medicament includes the nasal cavity.

[0065] The present invention will be illustrated below with specific examples.

[0066] [,experiment , ] [, 1 Potassium channel openers can be used as a treatment for L-DOPA-induced dyskinesia.

[0067] In this experiment, the testing of abnormal involuntary movements included two types of involuntary movements (AIMs): axial dyskinesia and limb dyskinesia. AIMs were mainly characterized by contralateral twisting and abnormal muscle tone, while limb dyskinesia included forelimb tremors and tic-like movements. For axial AIMs, a baseline severity score was first assigned, where 0 indicated no rotation, 1 indicated a rotation duration of less than 30 seconds, and 2 indicated a rotation duration of more than 30 seconds. This score was then multiplied by an AIM amplitude scale, with the following scoring criteria: 0 for no rotation, 1 for fewer than 10 rotations, 2 for 11 to 20 rotations, 3 for 21 to 30 rotations, and 4 for 31 to 40 rotations. In the scoring of limb-type AIM, the baseline severity score is multiplied by the postural score. The baseline severity score is defined as follows: 0 points indicate no tremor, 1 point indicates tremor lasting less than 30 seconds, and 2 points indicate tremor lasting more than 30 seconds. The postural score is defined as follows: 0 points indicate no flapping, 1 point indicates movement accompanied by locomotion flapping and paw shaking, 2 points indicates locomotion flapping accompanied by shaking of the entire arm, and 3 points indicates arm shaking accompanied by shoulder and back movement. In addition, the number of complete rotations to the contralateral side is assessed to determine whether D3 receptor manipulation affects levodopamine-induced motor activity.

[0068] In this experiment, an animal model was first established. In this example, male mice of strain C57BL / 6, aged 8 weeks, were used. Referring to Figure 1, the establishment of the Parkinson's disease (PD) mouse involved: administering 6-hydroxydopamine (6-OHDA) to the mice via unilateral injection using a 10 μL syringe, with the injection coordinates relative to the frontal vertex (mm): anteroposterior +0.14, lateral +2.1, dorsoventral -3.5, for a period of 3 weeks; subsequently, the PD mouse was intraperitoneally injected with levodopa (L-DOPA) once daily for 2 weeks, thus obtaining the L-DOPA-induced involuntary movement (LID) mouse.

[0069] In Figure 1, at week 0, mice in the control group received an injection of 0.02% ascorbic acid into both the left and right hemispheres of the brain via striatum. Mice in the experimental group received an injection of 4 μg / μL of hydroxydopamine (6-OHDA) in saline containing 0.02% ascorbic acid into the left hemisphere, thereby inducing damage to the left hemisphere (damaged side). The right hemisphere received only 0.02% ascorbic acid, without causing damage (undamaged side). From week 3 onwards, both the control and experimental groups received intraperitoneal injections of levodopa (L-DOPA) and a benzerazide until week 5. Starting from the third week, the abnormal involuntary movements test (AIMs test) was performed on day 1, day 6 and day 13.

[0070] Referring to Figure 2, it illustrates that by performing immunohistochemical staining on tyrosine hydrolase (TH), the abundance and distribution of TH+ neurons containing tyrosine hydrolase can be identified in mouse brain images, including images of the striatum (STR) and substantia nigra (SN). In other words, in the brain images, the darker areas indicate the presence of more neurons containing tyrosine hydrolase.

[0071] As can be seen from the images, those lesioned by hydroxydopamine show lighter staining, indicating a decline in the number of neurons containing tyrosine hydroxylase. This result suggests that dopamine secretion will decline, becoming a representative symptom of Parkinson's disease. Continuing to refer to Figures 3A and 3B, using the Abnormal Involuntary Movement Test (AIM), it can be observed that as the levodopa injection schedule progresses, the forelimb AIM score and axial AIM score also increase, indicating more severe involuntary movements.

[0072] Referring to Figure 4, it is used to illustrate the efficacy of potassium ion channel openers in levodopam-induced involuntary movement in mice; among them, the experimental groups were given: (1) carrier (88% polyethylene glycol (PEG), 10% dimethyl sulfoxide (DMSO), 2% Tween 80), (2) potassium ion channel opener: diazoxide (Diz), or (3) potassium ion channel blocker: glibenclamide (Gbc), which were given in the 3rd week and the administration period was 2 weeks. Based on the aforementioned levodopa-induced involuntary movement mouse model, from week 3 to week 5, the catheter was placed in the striatum using an implanted drug delivery pump (mini-osmotic pumps, Alzet®, 1002), with coordinates (mm): anteroposterior +0.14, lateral +2.1, dorsoventral -3.5, and diazoxide was administered at a rate of 0.26 μL / h.

[0073] Referring to Figure 5A, immunohistochemical staining of neurons containing tyrosine hydroxylase, and referring to Figures 5B and 5C, it can be clearly seen that administration of diazoxide can induce the number of neurons containing tyrosine hydroxylase to recover to near the control group (CTR). Further referring to Figures 6A and 6B, in terms of abnormal involuntary movement test (AIM), the test score (AIM score) of the potassium channel opener group is significantly lower than that of the potassium channel blocker group and the carrier group, and is closer to the healthy control group.

[0074] Experiment 1 shows that by implanting potassium ion channel openers into the striatum, the abnormal involuntary movement test score (AIM score) can be reduced, that is, the levodopa-induced involuntary movements are reduced.

[0075] [, experiment , ] [, 2 , ]: Microcells, their encapsulation of potassium ion channel openers, and the interaction between microcells encapsulating potassium ion channel openers and nasal mucosal cells.

[0076] Please refer to Figure 7A, which shows the steps S for the synthesis and detection of microcells, including: fluorescent molecule synthesis step S1, polymer polymerization step S2, microcell molecule synthesis step S3, microcell assembly step S4, and microcell detection step S5.

[0077] In step S1 of the fluorescent molecule synthesis, the reaction shown in Figure 8A occurs to synthesize the monomer of the fluorescent molecule (3-(1,3-dioxo-6-(pyrrolidine-1-yl)-1H-benzo-isoquinolin-2(3H)-yl) propanoic acid, PNA).

[0078] Specifically, 2 g (7.2 mmol) of 4-bromo-1,8-naphathalic anhydride and 0.965 g (10.8 mmol) of β-alanine were dissolved in 40 mL of anhydrous ethanol and placed in a three-necked flask equipped with a reflux tube. The mixture was reacted in an oil bath at 72 °C and 700 rpm for 24 hours under a nitrogen atmosphere to obtain a crude product. The crude product was separated into a white product by vacuum filtration. The white product was repeatedly washed with anhydrous ethanol and then placed in a vacuum oven at 60 °C for 24 hours to obtain a white solid. The degree of reaction completion of the crude product was determined by TLC chromatography (DCM / MeOH=8 / 1, v / v), and the structure and purity of the white solid were determined by 1H NMR (400 MHz, DMSO-d6).

[0079] 1 g (2.87 mmol) of the white solid and 0.245 g (3.45 mmol) of pyrrolidine were dissolved in 25 mL of 2-methoxyethanol and placed in a three-necked flask equipped with a reflux tube. The mixture was heated to reflux at 120 °C for 48 hours. The degree of completion of the reaction was determined by TLC chromatography (DCM / MeOH=8 / 1, v / v). The three-necked flask was then cooled to room temperature and 150 mL of sodium chloride was added. The mixture was then extracted three times with 200 mL of ethyl acetate each time. The organic layer was collected and an appropriate amount of anhydrous sodium sulfate was added for a certain period of time to remove residual water. The mixture was then filtered under vacuum. The filtrate obtained after vacuum filtration was further concentrated under reduced pressure to remove ethyl acetate, then heated to boiling with 40 mL of anhydrous ethanol, and subsequently recrystallized in an ice bath. The crystallized product was placed in a vacuum oven at 50 °C for 24 hours to obtain an orange powder, the structure and purity of which could be determined by 1H NMR (400 MHz, DMSO-d6).

[0080] In the polymer polymerization step S2, the reaction shown in Figure 8B occurs to synthesize the polymer mPEG-b-PCL.

[0081] A Schlenk flask containing 3 g of mPEG was dried in a vacuum oven at 60 °C for 24 hours. After cooling, 7.54 g (66 mmol) of ε-caprolactone and 0.105 g (0.259 mmol) of Sn(OCt)2 (stannous 2-ethylhexanoate) were added under a nitrogen atmosphere, and the mixture was reacted in an oil bath at 124 °C for 24 hours to obtain a yellow viscous substance. The yellow viscous substance was placed in an ice bath, and a small amount of tetrahydrofuran (THF) was added to it. Diethyl ether was then added and stirred to precipitate a white solid. The white solid was collected by vacuum filtration and then reconstituted with a small amount of tetrahydrofuran (THF). The solid was then precipitated with ice-cold diethyl ether. This process was repeated 2 to 3 times. The solid was then placed in a vacuum oven at room temperature for 24 hours to obtain a white particulate product. The structure and purity of the white particulate product were determined by 1H NMR (400 MHz, CDCl3), as shown in Figure 9A.

[0082] In step S3 of the microcellular molecule synthesis, the Steglich esterification reaction shown in Figure 8C occurs to synthesize the microcellular molecule poly(ethylene glycol)-b-poly(ε-caprolactone)-3-(1,3-dioxo-6-(pyrrolidine-1-yl)-1H-benzo-isoquinolin-2(3H)-yl) propanoic acid, which is also referred to as PPP or mPEG-b-PCL-PNA.

[0083] Prepare 3 g (0.426 mmol) of dried high-molecular-weight mPEG-b-PCL and place it in a Schlenk flask. Add 0.026 g (0.213 mmol) of 4-DMAP (4-dimethylaminopyridine) to the flask, remove air by vacuum, and introduce nitrogen. Dissolve the mPEG-b-PCL in 8 mL of dichloromethane (DCM) under nitrogen atmosphere. Separately, dissolve 0.26 g (0.768 mmol) of the fluorescent molecule PNA in 0.204 g (1.064 mmol) of the coupling reagent EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide) in a sample vial and introduce nitrogen into the vial. Then, inject the solution from the sample vial into the Schlenk flask using a plastic syringe and react at 30 °C for 24 hours to obtain a crude product.

[0084] The crude product was dialyzed with deionized water (DI water) for 48 hours, followed by dialyzed with tetrahydrofuran (THF) for another 48 hours. The dialysate was then added dropwise to ice-cold diethyl ether, and a yellow solid was precipitated by rapid stirring. The yellow solid was collected by vacuum filtration and then reconstituted with a small amount of tetrahydrofuran (THF). The solid was then precipitated again with ice-cold diethyl ether, and this process was repeated 2 to 3 times. The solid was then placed in a vacuum oven at room temperature for 24 hours to obtain a yellow particulate product. The structure and purity of the yellow particulate product were determined by 1H NMR (400 MHz, CDCl3), as shown in Figure 9B.

[0085] In the microcell assembly step S4, the aforementioned microcell molecules undergo a self-assembly reaction to obtain a microcell or a microcell coated with a drug.

[0086] To prepare the microcells, 3 mg of PPP was dissolved in 0.6 mL of tetrahydrofuran (THF) to obtain a mixed solution. This mixed solution was injected into phosphate-buffered saline (PBS) at a rate of 25 μL / min using a syringe with continuous rapid stirring, allowing the microcell molecules to self-assemble and obtain a first microcell solution containing 1 mg of microcells per mL. Subsequently, the solution was dialyzed with 0.001 M phosphate-buffered saline and a dialysis membrane (MWCO 3500) to remove THF, and then filtered through a 0.45 μm polytetrafluoroethylene (PTFE) membrane filter to obtain a second microcell solution.

[0087] To prepare drug-coated microcells, diazoxide was dissolved in dimethyl sulfoxide (DMSO) to obtain a drug stock solution with a concentration of 5 mg / mL. On the other hand, to determine the different effects of microcellular molecules to drug weight ratios of 10:1, 20:1, and 30:1, 3 mg of PPP was dissolved in a corresponding volume of tetrahydrofuran (THF) to obtain a mixed solution with corresponding volumes of 0.54 mL, 0.57 mL, and 0.58 mL, respectively. Then, 0.06 mL of the drug stock solution was thoroughly mixed with 0.54 mL of the mixed solution (weight ratio 10:1), or 0.03 mL of the drug stock solution was thoroughly mixed with 0.57 mL of the mixed solution (weight ratio 20:1), or 0.02 mL of the drug stock solution was thoroughly mixed with 0.58 mL of the mixed solution (weight ratio 30:1). Then, 2.4 mL of 0.01 M phosphate-buffered saline was added, and the mixture was homogenized by ultrasound at 4°C at 750 w × 10⁻⁶. The solution was homogenized at 25% concentration, intermittently (9 seconds on / 4 seconds off) for 15 minutes, to obtain solutions of drug-coated microcells with different microcell molecule / drug weight ratios. Next, the solution was dialyzed using 0.001 M phosphate-buffered saline and a dialysis membrane (MWCO 3500) to remove tetrahydrofuran (THF), dimethyl sulfoxide (DMSO), and uncoated diazoxide, yielding a drug-coated microcell solution containing the drug-coated microcells.

[0088] Please refer to Figure 7B. The microcell detection step S5 includes a microcell size and arrival potential detection step S51. The microcell size and arrival potential are detected using a dynamic light scattering particle size analyzer (DLS) to measure the size and arrival potential of the microcells contained in the second microcell solution. Measurement parameters are set as follows: angle 90°, temperature 25°C, and temperature equilibration time 2 minutes. During measurement, 1 ml of the second microcell solution is added to a cuvette, and the average of three measurements is used as the measured value. Please refer to Table 1, which shows the properties of the microcell and the diazoxide-coated microcells; in Table 1, the diazoxide-coated microcells are labeled "PPP-D".

[0089] Table 1 Feed weight ratio (PPP:D) Particle size (nm) polydispersity index (PDI) Boundary potential (mV) microcells -- 44.2 ± 0.08 0.145 ± 0.024 -9.3 ± 0.07 PPP-D 10:1 56.9 ± 0.11 0.205 ± 0.019 -5.7 ± 0.16 PPP-D 20:1 53.3 ± 0.03 0.139 ± 0.016 -6.2 ± 0.12 PPP-D 30:1 51.5 ± 0.03 0.127 ± 0.027 -12.1 ± 0.0

[0090] Please refer to Figure 7B. The microcell detection step S5 includes drug encapsulation efficiency (EE) and loading capacity (LC) detection steps S52. A quantitative amount of microcells or drug-coated microcells are freeze-dried and weighed, dissolved in a quantitative amount of dimethyl sulfoxide (DMSO), and then the absorbance is measured using a UV-Vis spectrometer (Shimadzu UV-2600) at a specific wavelength, such as 272 nm corresponding to diazoxide. The concentrations of the fluorescent molecule PNA in DMSO (including 447 nm and 272 nm, as shown in Figures 10A and 10B respectively) and the drug diazoxide in DMSO (as shown in Figure 10C) are calculated and obtained. Further data are derived using Equations 1 and 2. Please also refer to Table 2, which shows the properties of the diazoxide-coated microcells (PPP-D).

[0091] Formula 1:

[0092] Formula 2:

[0093] Table 2 serial number Feed weight ratio (PPP:D) EE (%) LC (%) 1 10:1 18.36 ± 2.06 1.02 ± 0.09 2 20:1 11.14 ± 0.51 0.47 ± 0.11 3 30:1 7.95 ± 0.20 0.36 ± 0.13

[0094] As shown in Table 2, the drug loading capacity (LC) of the diazoxide-coated microcells numbered 1 was the highest. Therefore, unless otherwise specified, subsequent experiments mainly used the diazoxide-coated microcells synthesized at a feed weight ratio (PPP:D) of 10:1.

[0095] Please refer to Figure 7B. The microcell detection step S5 includes a stability detection step S53. On the one hand, a quantitative amount of microcells or drug-coated microcells are taken and placed in environments of 4°C and 37°C for 28 days, during which time changes in appearance color and turbidity are collected and recorded. On the other hand, a dynamic light scattering particle size analyzer (DLS) is used to detect changes in microcell size and boundary potential on days 1, 7, 14, 21 and 28.

[0096] Regarding the changes in appearance color and turbidity, please refer to Figure 11A. It can be clearly observed that the solution containing diazoxide-coated microcells remained clear throughout the 28-day period, regardless of whether the environment was 4℃ or 37℃. Regarding the results of microcell particle size and zeta potential, please refer to Figure 11B. In both 4℃ and 37℃ environments, the ratio of Dt to D0 remained stable at approximately 1.0 throughout the 28-day period, indicating good dispersion and stability. Simultaneously, referring to Figure 11C, the zeta potential observed showed that the diazoxide-coated microcells maintained a comparable zeta potential value in both 4℃ and 37℃ environments. Therefore, the diazoxide-coated microcells prepared by the aforementioned method possess considerable stability.

[0097] Next, this experiment will use microcell penetration experiments to demonstrate that microcells coated with diazoxide are more suitable for penetrating a nasal epithelial cell layer model than diazoxide alone.

[0098] For the establishment of the nasal epithelial cell layer model, the cell line used was human nasal septum squamous cell carcinoma (RPMI2650); the culture medium was minimum essential medium (MEM), supplemented with fetal bovine serum (FBS), sodium pyruvate, and non-essential amino acids (NEAA).

[0099] Furthermore, the cell line was prepared with a stock solution of 2.5 × 10⁶ / mL. 0.25 mL of this stock solution was added to the insert in the Transwell plate, and the cells were cultured at 37°C and 5% CO₂ for 24 hours to allow the cells to adhere to the bottom of the insert. Then, the culture medium in the insert was removed, allowing the cells to be cultured at an air-liquid interface (ALI) for 14 days to allow cell differentiation into a cell layer. The culture medium in the well plate was replaced with fresh medium every 2 to 3 days, and the transepithelial electric resistance (TEER) of the cell layer was measured daily. After 14 days of culture, the establishment of the nasal epithelial cell layer model was confirmed using a Millicell® ERS-2 voltmeter. The model was considered established when the transepithelial electric resistance reached 120 ohms (Ω).

[0100] Regarding the drug dosage correspondence, as mentioned above, the drug concentration required for each diazoxide-only group is estimated based on the drug loading capacity (LC) of the diazoxide-coated microcells, thereby providing a comparative benchmark for diazoxide. Refer to Table 3, which shows the proportion of drug concentrations corresponding to diazoxide-coated microcells.

[0101] Table 3 serial number PPP-D (mL) MEM (mL) Diazoxide (μg / mL) 1 0.654 0.346 20 2 0.327 0.673 10 3 0.163 0.837 5 4 0.082 0.918 2.5 5 0.041 0.959 1.25 6 0.020 0.980 0.625

[0102] Next, corresponding to number 1 in Table 3, after replacing the old culture medium and washing, microcells coated with diazoxide were introduced into the insert as the first experimental group. On the other hand, diazoxide alone was introduced into the insert as the second experimental group. Both were incubated at 37°C and 5% CO2 for 4 hours. One milliliter of phosphate-buffered saline was added to each of the wells in both the first and second experimental groups to collect components that permeated through the nasal epithelial cell layer. After 4 hours of incubation, the phosphate-buffered saline in the wells was removed, and the absorbance was analyzed using UV-Vis spectroscopy. The absorbance was then compared to the drug's calibration curve in phosphate-buffered saline (Figure 12A) to determine the drug concentration. The permeability (Papp) was then calculated using Equation 3.

[0103] Formula 3:

[0104] In Equation 3, [C]A (mg / mL) represents the concentration difference of the solution in the well plate, [C]D (mg / mL) represents the initial concentration in the well plate, VA (mL) represents the total volume in the well plate (i.e., 1 ml), and A (cm2) is the surface area of ​​the nasal epithelial cell layer (1.13 cm2). t is the infiltration time (seconds, sec).

[0105] Referring to Figure 12B, it can be understood that the permeability coefficient (Papp, 10⁻⁶ cm / s) of microcells coated with diazoxide is significantly higher than that of free diazoxide (alone), with a difference of approximately 4 times. This result shows that the microcellular form of diazoxide is more likely to pass through the nasal epithelial cell layer than the free form, thus having the opportunity to enter the nasobrain pathway.

[0106] [, experiment , ] [, 3The combination of potassium ion channel openers and microcells can cross the blood-brain barrier (BBB) ​​via the nasobrain pathway, thereby achieving the therapeutic effect of L-DOPA-induced dyskinesia and the effect of regulating endocrine function.

[0107] The diazoxide-coated microcells used in this experiment were prepared according to Experiment 2 described above. The animal experiments used 8-week-old male C57BL / 6 mice, housed in an environment with constant temperature, humidity, and circadian rhythms. Unless otherwise specified, water and food were provided freely.

[0108] In some embodiments of this experiment, the test for assessing abnormal involuntary movements in mice qualitatively and quantitatively characterized the mice's motor features, including forelimb and axial movement disorders. During the test, after administration of levodopamine, the mice were placed in a transparent, observable cylinder for at least 140 minutes, with their movements recorded every 20 minutes. The specific scoring method is described in Experiment 1 above regarding the abnormal involuntary movement test. Thus, throughout the treatment period, the scores of various types of involuntary movement (dyskinesia) can be summed to obtain a total abnormal involuntary movement score (total AIM score), which is then used for subsequent data analysis.

[0109] In some embodiments of Experiment 3, techniques such as Western blot, immunohistochemistry staining, immunofluorescence staining, and gene expression analysis including RT-qPCR were applied; however, these techniques are well known to those skilled in the art and will not be described in detail here.

[0110] First Example: To verify the transport pathway of diazoxide-loaded micelles, a solution of diazoxide-loaded micelles was administered into the nostrils of mice using a micropipette, allowing them to breathe naturally and thus aspirate the diazoxide-loaded mice into their nasal cavities. The volume of the solution administered into each nostril was 125 μL, and the total amount of diazoxide-loaded mice administered was 0.04 mg / kg.

[0111] Next, the olfactory tubercle region of mice was isolated and immunofluorescence stained to assess whether the diazoxide-coated microcells migrated to this region. Please observe Figure 13. The left half of Figure 13 shows the results of the control group, which was not given diazoxide-coated microcells and therefore did not produce a fluorescent signal; the right half of Figure 13 shows the experimental group, which was given diazoxide-coated microcells and thus produced a fluorescent signal. It should be understood that the olfactory tubercle region is located in the forebrain and is part of the central nervous system.

[0112] Second embodiment: To verify the effect of diazoxide-coated microcells, a unilateral nigrostriatal lesion mouse model was first established, inducing Parkinson's disease symptoms in this mouse model. Then, based on the aforementioned unilateral nigrostriatal lesion model, a L-DOPA-induced dyskinesia model was further established.

[0113] Referring to Figure 14, to establish the substantia nigra striatum lesion model, mice were anesthetized with isoflurane and then administered 6-OHDA. Prior to administration, 6-OHDA was dissolved in physiological saline containing 0.02% ascorbic acid at a concentration of 4 μg / μL. Administration was performed using a 10 μL syringe, with injection sites based on the relative coordinates (mm) of the frontal vertex: anteroposterior +0.14, lateral +2.1, and dorsoventral -3.5, at a rate of 1 μL / min. To establish the levodopa-induced involuntary movement model, levodopa was administered under the following conditions: a dose of 10 mg / kg per administration, daily administration, and a duration of 4 weeks, thereby inducing involuntary movement.

[0114] As the experimental group, diazoxide-coated microcells were administered to levodopamine-induced involuntary movement model mice (LID mice) at a dose of 0.04 mg / kg via nasal administration, daily for 4 weeks. As the control group, FAUC-365 (a dopamine D3 receptor antagonist), known for its efficacy against involuntary movement, was administered to another levodopamine-induced involuntary movement model mouse at a dose of 3 mg / kg via intraperitoneal injection, daily for 4 weeks. Both the experimental and control groups received levodopamine.

[0115] Please refer to Figures 15A and 15B. The axial fraction and forelimb fraction in the involuntary movement score were measured separately. It is understood that, at later time points, the symptoms of involuntary movement were more significantly relieved by intranasal administration of diazoxide-coated microcells and by intraperitoneal injection of FAUC-365.

[0116] Furthermore, to illustrate the neuroprotective effect of diazoxide-coated microcells in a hydroxydopamine-induced model, immunohistochemical staining was used to observe the distribution of tyrosine hydroxylase (TH) in the striatum (STR) and substantia nigra (SN) of mice. It should be understood that this tyrosine hydroxylase is a rate-determining enzyme for dopamine production in dopamine-producing neurons. Therefore, in the induced group, the left hemisphere of the mice was injected with 4 μg / μL hydroxydopamine (6-OHDA) as the injured side, while the right hemisphere was injected with saline containing 0.02% ascorbic acid as the uninjured side. The treatment group consisted of mice treated with diazoxide-coated microcells, similar to the induced group. As a control group, the left and right hemispheres of the mice were injected with saline containing 0.02% ascorbic acid, which did not cause any damage.

[0117] Please refer to the mouse brain images in Figure 16A and the quantitative diagram provided in Figure 16B. In the control group, the tyrosine hydroxylase levels in both the left and right striatums were normal, indicating a higher number of synapses and neurons. In the lesion group, the tyrosine hydroxylase content on the injured side was significantly reduced compared to the control group. Further observation in the treatment group revealed that after intranasal administration of diazoxide-coated microcells, the tyrosine hydroxylase content on the injured side increased, even approaching the levels seen in the control group. This indicates a recovery in the number of synapses and neurons and a reversal of the damage.

[0118] It can be inferred from this that microcells coated with diazoxide can prevent the loss of neurons, or in other words, can prevent further neuronal degeneration.

[0119] To further understand the distribution of diazoxide-coated microcells in the brain, at the end of the animal experiments, mouse brains were collected for immunofluorescence staining of tyrosine hydroxylase (TH); continuous coronal sections from the prefrontal cortex to the cerebellum were collected. Referring to Figure 17, it can be seen that diazoxide-coated microcells with green fluorescence were mainly detected in the frontal brain regions. Stronger green fluorescence was concentrated in the prefrontal cortex of the damaged hemisphere, indicating stronger absorption by diazoxide-coated microcells. For the nigrostriatal pathway, corresponding to the distribution of tyrosine hydroxylase, green fluorescence can be detected in the striatum, indicating that diazoxide-coated microcells reach the dopaminergic terminals of dopamine neurons; however, green fluorescence cannot be detected in dopamine neurons in the substantia nigra.

[0120] Therefore, when diazoxide-coated microcells are delivered via the nasal route, they mainly accumulate in the forehead and striatum; thus, their potential role in regulating dopamine function and their ability to alleviate levodopa-induced involuntary movements can be understood.

[0121] Third Example: To verify the effect of diazoxide-coated microcells on glucose homeostasis, this example performed an insulin tolerance test (ITT) and a glucose tolerance test (GTT). Referring to Figure 18A, which shows the results of the ITT, plasma glucose concentrations decreased in all groups 30 to 60 minutes after administration of insulin (0.75 units / kg). However, the decrease was more pronounced in the LID group, indicating increased insulin sensitivity. Referring to Figure 18B, which shows the results of the glucose tolerance test, plasma glucose concentrations peaked at 15 minutes in all groups and then gradually decreased. This glucose clearance pattern is understandably similar across groups; in other words, administration of FAUC-365 or intranasal administration of diazoxide-coated microcells can neutralize / normalize the increased insulin sensitivity in the LID mice.

[0122] These results show that although LID mice exhibited high insulin sensitivity, this sensitivity was regulated back to normal after administration of FAUC-365 or intranasal administration of diazoxide-coated microcells, and there was no significant effect on glucose tolerance (no statistical difference); in other words, the metabolic regulation function of LID mice remained normal after administration of FAUC-365 and diazoxide-coated microcells.

[0123] The above description is merely a few preferred embodiments of the present invention and should not be construed as limiting the scope of the present invention. In other words, any equivalent changes or simple modifications made in accordance with the technical essence of the present invention or the embodiments should still be covered within the scope of the present invention patent application.

[0124] S: Steps for the synthesis and detection of microcells S1: Fluorescent molecule synthesis steps S2: Polymerization Step S3: Cellular molecular synthesis steps S4: Microcell Assembly Steps S5: Microcell Detection Steps S51: Procedure for Detecting Cell Size and Attack Potential S52: Procedures for Testing Drug Encapsulation Efficiency and Capacity S53: Stability Testing Procedure

[0125] none

Claims

1. The use of a microcellular composition containing diazoxide in the preparation of a drug, wherein, This drug is used to prevent or treat levodopa-induced involuntary movements in individuals with Parkinson's disease after levodopa treatment. The diazoxide is embedded or encapsulated in the microcells, which are formed by a block copolymer, mPEG-b-PCL or mPEG-b-PCL-PNA, and the drug is administered via the nasal cavity.

2. The use as described in claim 1, wherein, The drug is available in liquid, dry powder, suspension, or any combination thereof.

3. The use as described in claim 1, wherein, The particle size of the microcell is between 35 nanometers and 70 nanometers, and the boundary potential of the microcell is between -15 millivolts and -2 millivolts.

4. The use as described in claim 1, wherein, The weight ratio of the diazine to the microcell is 1:(100 to 1500).

Citation Information

Patent Citations

  • Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome

    US20160136178A1

  • Controlled-delivery cromakalim prodrugs

    US20220324890A1